Revlimid News and Research

RSS
Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Yale study identifies how myeloma cells escape treatment

Yale study identifies how myeloma cells escape treatment

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

IMF announces approval of POMALYST medication in Canada for patients with myeloma

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID